stratification, and transwell culture further enhanced stratification. OCT showed that the urothelium with transwell culture was generally thicker than in a normal dish. In an immunohistological analysis, stratified uroplakin II-positive epithelium was observed in transwells.
INTRODUCTION AND OBJECTIVES:
Mesenchymal stem cells (MSC) have shown great promise with respect to the prevention and treatment of detrusor dysfunction and fibrosis after partial bladder outlet obstruction (pBOO). Our lab has previously demonstrated short and longterm benefits with a reduction in the inflammatory and hypoxic cytokine cascade, decreased smooth muscle hypertrophy, prevention of fibrosis, and improvement in urodynamic parameters. Although our intravenous administration has demonstrated uptake of MSC into the bladder, we hypothesize the primary mechanism of action is via a systemic downregulation of the inflammatory and hypoxic cascade. Therefore, we repeated the pBOO in our model using the intraperitoneal (IP) administration of MSC to compare the efficacy to intravenous administration.
METHODS: 5x106 MSC via IP had similar effects to 106 MSC IV, while 106 IP was not as effective. 5 x106 IP showed greater reduction in TGF-B1, MTOR, and Col 1þ3 than 106 IV (p<0.05) at 4 weeks. The difference was less pronounced after 2 weeks. MSC benefits were seen with respect to decreased hypoxic markers (HIF-1, HIF-3) and improved urodynamic parameters, with the high dose IP results similar to the IV administration. IHC demonstrated uptake of MSC in the detrusor with IV, but not with IP dosing.
RESULTS: 5x106 MSC via IP had similar effects to 106 MSC IV, while 106 IP was not as effective. 5 x106 IP showed greater reduction in TGF-B1, MTOR, and Col 1þ3 than 106 IV (p<0.05) at 4 weeks. The difference was less pronounced after 2 weeks. MSC benefits were seen with respect to decreased hypoxic markers (HIF-1, HIF-3) and improved urodynamics, with the high dose IP results similar to the IV administration. IHC demonstrated MSC in the detrusor with IV, but not with IP dosing. CONCLUSIONS: We have been able to show that IP MSC administration is effective in a dose and time dependent manner. IP compares favorably to IV administration but requires greater dosing. Its mechanism of action, however, may demonstrate a distant response to systemic inflammation compared to detrusor implantation and direct, paracrine responses. This has significant implications with respect to the comprehension of the mechanism of action and progression to clinical use. (FSUI) is prevalent in women with type 2 diabetes/obesity (T2D/O), and treatment is not optimal. Stem cells (SC) may repair endogenously the damaged bladder urethral myosphincter (BUM), but have poor efficacy in SC therapy, usually as autografts. In the male Zucker fatty (ZF) rat model of T2D/O with erectile dysfunction, the repair capacity of muscle derived SC (MDSC) is impaired in aging by a longterm exposure to dyslipidemic milieu, that triggers a noxious phenotype and abnormal global transcriptional signatures (GTS) of genes and microRNAs (miRs). This is mimicked in vitro by treatment of MDSC with dyslipidemic serum or lipid factors. In order to predict whether SC damage occurs in T2D/O-associated FSUI, impairing their endogenous and SC therapy repair capacity, we studied whether: 1) the dyslipidemic serum from aged female ZF rats (ZF-S) damages in vitro the SC from young normoglycemic ZF rats (ZF-SC), in comparison with serum from control Zucker lean rats (ZL-S), and 2) the ZF-SC are more impaired than the SC from ZL rats (ZL-SC).
METHODS: ZF-SC and ZL-SC from pelvic muscles were incubated in DMEM/ serum, with added either dyslipidemic ZF-S or normolipidemic ZL-S (1-5%), or no addition (NA). At 4 days: a) quantitative histochemistry measured fat deposits (Oil red O), apoptosis (Tunel), and scratch wound repair (HE), b) western blots measured proliferation (PCNA), smooth muscle (calponin 1) and skeletal myofiber (MHC-II) differentiation, and a muscle inhibitor/prolipofibrotic factor (myostatin), and c) miR-GTS were determined.
RESULTS: ZF-S compared with NA increased similarly fat infiltration and apoptosis in the ZF-SC and ZL-SC, reduced % gap closure (11-vs 3-fold), and SC proliferation and differentiation, but increased myostatin. ZL-S was nearly ineffective. Many individual miRs in untreated ZF-SC and ZL-SC compared with male MDSC, varied >2 fold (e.g., lower 100-5p, 99a-5p; higher 143-3p, 221-5p), as well as between themselves. Treatment with ZF-S, but not ZL-S, reduced miRs decreased in MDSC by the T2D/O milieu, related to myostatin inhibition (e.g., 21-5p, 199a-5p) or unrelated (e.g., 99b-5p, 10b-5p) .
CONCLUSIONS: The dyslipidemic ZF-S damages both SC in vitro, and up-regulates myostatin, in agreement with miR-GTS changes, thus resembling the male ZF rat model. This predicts noxious effects in vivo of the T2D/O milieu impairing endogenous SC tissue repair and autograft SC therapy for FSUI.
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INTRODUCTION AND OBJECTIVES: The efficacy of phosphodiesterase type 5 inhibitors (PDE5I), which are commonly used to treat erectile dysfunction (ED), is not satisfactory in patients with diabetes mellitus and denervation of the cavernous nerve due to pelvic surgeries. Preclinical studies using bone marrow-derived mesenchymal stem cells (BMSCs) to treat ED have shown promising results. We
